Patients with chronic hepatitis C and vitamin D deficiency who were treated with direct-acting antivirals did not achieve significant improvements in serum fibrogenesis markers after taking vitamin D supplements for six weeks, compared with those who took a placebo, according to a study by Piyawat Komolmit of Chulalongkorn University in Thailand and colleagues. The findings, published in PeerJ, suggest that short-term vitamin D supplementation does not help boost the healing process of residual liver fibrosis.
Vitamin D doesn't affect residual liver fibrosis in CHC
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.